Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VAC 2

Next Previous
X
Search
Drug Profile

VAC 2

Alternative Names: AST-VAC 2; Dendritic cells - Lineage Cell Therapeutics; GRNVAC 2; VAC2

Latest Information Update: 15 Sep 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Geron Corporation
  • Developer Asterias Biotherapeutics; Cancer Research UK; Lineage Cell Therapeutics
  • Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-small cell lung cancer
  • Discontinued Transplant rejection

Most Recent Events

  • 13 Sep 2023 VAC 2 is still in phase I trial for Non-small cell lung cancer in the United Kingdom
  • 28 Aug 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (Intradermal, Injection)
  • 24 Jul 2023 Efficacy and adverse events data from a phase-I trials in Non-small cell lung cancer released by Lineage Cell Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top